Status:
UNKNOWN
Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia
Lead Sponsor:
Medical University of Lodz
Conditions:
Schizophrenia
Eligibility:
All Genders
16-35 years
Phase:
PHASE4
Brief Summary
There is accumulating experimental evidence to suggest the role of essential fatty acids (EFA) in neuronal migration, pruning and synaptic plasticity. These processes are implied to be dysfunctional o...
Eligibility Criteria
Inclusion
- Patients diagnosed with schizophrenia using Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria
- Patients aged between 16-35 years
- Signed informed consent (parallel parents consent for individuals under 18 years of age)
Exclusion
- Patients taking fish oil supplements (a washout period of 6 months is required)
- Patients diagnosed with epilepsy or suffering from epileptic seizures
- Patients receiving anticoagulant medication e.g., Warfarin
- Patients receiving psychotherapy
- Chronic somatic diseases
- Psychoactive substance dependence
- Pregnancy and lactation
- Mental retardation or diagnosed organic brain injury
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2015
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT02210962
Start Date
September 1 2011
End Date
February 1 2015
Last Update
February 18 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Affective and Psychotic Disorders Medical University of Lodz
Lodz, Łódź Voivodeship, Poland, 92216